A Phase 2b, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken at Bedtime in Patients With Fibromyalgia

Trial Profile

A Phase 2b, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Tablets Taken at Bedtime in Patients With Fibromyalgia

Completed
Phase of Trial: Phase II/III

Latest Information Update: 27 Dec 2016

At a glance

  • Drugs Cyclobenzaprine (Primary)
  • Indications Fibromyalgia
  • Focus Registrational; Therapeutic Use
  • Acronyms BESTFIT
  • Sponsors Tonix Pharmaceuticals Inc
  • Most Recent Events

    • 16 Nov 2016 Results of a pain responder analysis presented at the 80th American College of Rheumatology and the 51st Annual Meeting of the Association of Rheumatology and Health Professionals
    • 30 Sep 2016 Results of a retrospective analysis presented at the 16th World Congress on Pain.
    • 09 Jun 2016 Results of a retrospective analysis from Phase IIb part of the study published in Tonix Pharmaceuticals the Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top